Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for RSCF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -0.1674M
March 31, 2026 -0.2324M
December 31, 2025 0.1988M
September 30, 2025 0.3781M
June 30, 2025 0.2208M
March 31, 2025 0.0641M
December 31, 2024 -0.016M
September 30, 2024 -0.0723M
June 30, 2024 0.0033M
March 31, 2024 -0.1785M
December 31, 2023 -0.0615M
September 30, 2023 -0.0693M
June 30, 2023 0.2097M
March 31, 2023 -0.1829M
December 31, 2022 0.0572M
September 30, 2022 0.077M
June 30, 2022 -0.3318M
March 31, 2022 0.1056M
December 31, 2021 0.3299M
September 30, 2021 0.0863M
June 30, 2021 0.1509M
March 31, 2021 0.2643M
December 31, 2020 0.0723M
September 30, 2020 -0.0141M
June 30, 2020 -0.1307M
Date Value
March 31, 2020 0.0474M
December 31, 2019 0.0983M
September 30, 2019 0.2519M
June 30, 2019 -0.0497M
March 31, 2019 0.0354M
December 31, 2018 0.0528M
September 30, 2018 0.0248M
June 30, 2018 -0.099M
March 31, 2018 0.0068M
December 31, 2017 0.0605M
September 30, 2017 -0.0002M
June 30, 2017 -0.0581M
March 31, 2017 -0.0304M
December 31, 2016 -0.0509M
September 30, 2016 0.0807M
June 30, 2016 0.0585M
March 31, 2016 -0.1071M
December 31, 2015 -0.0471M
September 30, 2015 0.0351M
June 30, 2015 -0.0522M
March 31, 2015 0.0962M
December 31, 2014 0.0249M
September 30, 2014 -0.0357M
June 30, 2014 0.0427M
March 31, 2014 0.0779M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
West Pharmaceutical Services, Inc. 124.00M
Agilent Technologies, Inc. 519.00M
Anika Therapeutics, Inc. -0.684M
Bio-Rad Laboratories, Inc. 98.70M
Bruker Corp. -77.40M

Cash from Operations (Quarterly) Related Metrics